- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Extensive-stage primary small cell carcinoma of lung
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Atezolizumab – March 2020
Atezolizumab (SCLC): Solution concentrate for I.V. infusion 840 mg in 14 ml; Tecentriq®
Last updated
30 May 2025